2-4-3--5--tetrahydroxystilbene and Obesity

2-4-3--5--tetrahydroxystilbene has been researched along with Obesity* in 1 studies

Trials

1 trial(s) available for 2-4-3--5--tetrahydroxystilbene and Obesity

ArticleYear
Rich oleocanthal and oleacein extra virgin olive oil and inflammatory and antioxidant status in people with obesity and prediabetes. The APRIL study: A randomised, controlled crossover study.
    Clinical nutrition (Edinburgh, Scotland), 2023, Volume: 42, Issue:8

    Oleocanthal and oleacein are olive oil phenolic compounds with well known anti-inflammatory and anti-oxidant properties. The main evidence, however, is provided by experimental studies. Few human studies have examined the health benefits of olive oils rich in these biophenols. Our aim was to assess the health properties of rich oleocanthal and oleacein extra virgin olive oil (EVOO), compared to those of common olive oil (OO), in people with prediabetes and obesity.. Randomised, double-blind, crossover trial done in people aged 40-65 years with obesity (BMI 30-40 kg/m. A total of 91 patients were enrolled (33 men and 58 women) and finished the trial. A decrease in interferon-γ was observed after EVOO treatment, reaching inter-treatment differences (P = 0.041). Total antioxidant status increased and lipid and organic peroxides decreased after EVOO treatment, the changes reaching significance compared to OO treatment (P < 0.05). Decreases in weight, BMI and blood glucose (p < 0.05) were found after treatment with EVOO and not with OO.. Treatment with EVOO rich in oleocanthal and oleacein differentially improved oxidative and inflammatory status in people with obesity and prediabetes.

    Topics: Antioxidants; Cross-Over Studies; Female; Humans; Male; Obesity; Olive Oil; Prediabetic State

2023